Status:

WITHDRAWN

Clinical Effectiveness of Topical Autologous Platelet Gel for the Treatment of Venous Ulcers

Lead Sponsor:

National Healing Corporation

Conditions:

Venous Ulcer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare the effectiveness of standard venous ulcer care to standard venous ulcer care plus a cell based product made from the patients own blood. This product, Autologo...

Detailed Description

The purpose of this Pilot clinical study is to make a preliminary clinical and procedural assessment of the treatment of chronic venous stasis ulcers with Autologous Platelet Gel. The information and ...

Eligibility Criteria

Inclusion

  • Presence of venous insufficiency lower extremity (below knee) ulcer
  • 4 weeks
  • Area of ulcer is 1 cm2 - 20 cm2
  • Subject is receiving standard wound care
  • ABI ≥ 0.8 or, if diabetic, TBI ≥ 0.8 on the study limb.
  • Subject has adequate venous access for phlebotomy.
  • Subject has access to reliable outpatient dressing care (self, family member, nursing staff, etc.)
  • Hematocrit is \> 30%
  • Platelet Count is \> 100,000
  • INR \< 1.3
  • Subject has no known coagulopathies
  • Serum Albumin \> 2.5
  • If diabetic, HgbA1C \< 10%
  • Venous reflux \< 20 seconds by ultrasonography

Exclusion

  • Presence of arterial insufficiency (ABI or if diabetic TBI \<0.8)
  • Subject has received biological therapy within 30 days of enrollment
  • Subject is receiving radiation therapy near the ulcer
  • Active infection of the study wound, or osteomyelitis, or cellulitis has been diagnosed. The patient may be enrolled only after the infection has been controlled, including:
  • Debridement if necessary
  • Patient has received at least 2 weeks of appropriate antibiotics
  • Allergy to bovine thrombin
  • Alcohol or drug abuse within 6 months of enrollment
  • Subject has been diagnosed with AIDS, HIV, or Hepatitis
  • Subject is taking immunosuppressive therapy
  • Subject is taking pentoxyfilline (Trental®)
  • Steroid use within 7 days of enrollment
  • Presence of a non-study ulcer within 2.0cm of the study ulcer
  • Angioplasty by bypass or endovascular therapy within 4 weeks of enrollment
  • Suspected sleep apnea
  • Active Cancer
  • BMI \> 40 kg/m2
  • Severe Rheumatoid Arthritis
  • Collagen vascular disease
  • Female who is pregnant or lactating or not using a reliable birth control method if of child-bearing age
  • Wound bed with exposed bone, tendon, or fascia
  • Renal insufficiency defined as Creatinine \> 3 mg/dL
  • Hepatic insufficiency defined as total Bilirubin \> 2 mg/dL
  • Enrollment, within the past 3 months, in any study related to wound healing
  • Closure of study wound ≥ 40% within 2 screening visits of enrollment

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

End Date :

November 1 2006

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT00273234

Start Date

January 1 2006

End Date

November 1 2006

Last Update

March 6 2007

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Palms of Pasadena Wound Healing Center

St. Petersburg, Florida, United States, 33707

2

Parrish Wound Healing Clinic

Titusville, Florida, United States, 32796

3

Anna Jacques Hospital Wound Healing Center

Newburyport, Massachusetts, United States, 01950

4

Johnston Therapeutic Wound Clinic

Smithfield, North Carolina, United States, 27577